Hong Leong Bank Malaysia | Removal of Over-limit Fees

By Editorial Team -
Removal of Over-Limit Fees (for Credit Cards only)


"We would like to inform effective 1st October 2011, the Over-Limit fees of RM10 chargeable on each occurrence of over-the-limit, shall ceased.

Should you have any queries on this matter, please contact our Call Center at 03-76268899 or visit any of our branches."

More info:
http://www.hlb.com.my/pfs/latest/latest_notice57.jsp




Comments

Post a Comment

Pages

Popular posts from this blog

Top XRP ETFs to Watch in 2025: Dominating Holdings, Low Fees, and Performance Insights (December 2025 Update)

By -
Image
The XRP ETF ecosystem has exploded in November 2025, with four major U.S. spot ETFs launching between November 13 and November 24, driving cumulative inflows past $1 billion since Canary's (XRPC) debut. Regulatory tailwinds from the SEC's July 2025 guidance and Ripple's $125 million settlement have fueled this surge, alongside XRP's price holding above $2.20 (currently ~$2.22, up 1.4% intraday despite broader market volatility).  A fierce "fee war" has pushed U.S. spot expense ratios to historic lows (0.19–0.35%), with waivers extending through mid-2026 for many. Analysts now project $10–15 billion in total inflows over the next 12 months, as spot products capture 85%+ of flows. European and Canadian ETFs continue to thrive for regional investors, while futures-based options suit leveraged traders. On November 13, 2025, Canary Capital's Canary XRP ETF (ticker: XRPC) became the first pure-play spot XRP ETF to trade on a major U.S. exchange (Nasdaq). Its deb...
Read more

Top 10 Pharmaceutical Companies by Revenue and Market Cap in 2025 (November Edition)

By -
Image
The pharmaceutical industry continues to show robust performance in Q3 2025, with key players reporting strong sales driven by oncology, immunology, and metabolic drugs. Eli Lilly maintains its lead in market capitalization, fueled by high demand for its GLP-1 treatments Mounjaro and Zepbound, with projected full-year revenue growth of around 32%. Johnson & Johnson reported Q3 sales of $24.0 billion, up 6.8%, and raised its 2025 sales outlook. Roche achieved 7% sales growth in the first nine months to CHF 45.9 billion ($52.8 billion), raising its full-year guidance to mid-single-digit growth. Other top companies like AstraZeneca, Novartis, and Vertex reported double-digit growth in key segments. Challenges persist, including patent expirations and biosimilar competition, but new approvals and acquisitions signal continued innovation. This edition updates data with Q3 2025 figures where available. Credit:  fiercepharma.co...
Read more

Top 10 Food Companies by Revenue (2025)

By -
Image
Based on the most recent 2025 revenue data as of November 2025 (using trailing twelve months or fiscal 2024 figures where full calendar 2025 data is not yet available due to ongoing reporting), here are the top 10 food companies ranked by revenue. This update incorporates latest quarterly reports, TTM figures, and industry rankings from sources like Food Engineering's 2025 Top 100 Food and Beverage Companies, which notes PepsiCo surpassing Nestlé for the top spot based on reported sales. Top 10 Food Companies by Revenue (2025) This ranking reflects the largest companies primarily by annual revenue, emphasizing food production, processing, distribution, and retail sectors globally ( 1 ,  4 ). 1. Nestlé (Switzerland) Annual Revenue: USD  $113 billion ( nestle.com ) Key Brands: Nescafe, KitKat, Maggi, Purina, Waters Headquarters: Vevey, Switzerland Global Footprint: 188 countries Strategic Significance: World’s largest food manufacturer Notes:  World's largest food ...
Read more

Bitcoin Nasdaq Correlation: The Correlation between the Nasdaq index and Cryptocurrencies (2025 Year-End Version)

By -
Image
The correlation between the Nasdaq index and cryptocurrencies, particularly Bitcoin, has been a subject of interest and analysis, reflecting the increasing integration of digital assets into the broader financial ecosystem. Updated Status as of November 2025 The core thesis from the original article remains valid: Bitcoin continues to behave like a high-beta tech asset with a strong positive correlation to the Nasdaq 100. However, the relationship has evolved with some important nuances in 2025. 30-day rolling correlation (BTC vs. Nasdaq 100) : ~0.80 → Highest level since 2022 and the second-highest in the past decade (sources: Kobeissi Letter, Wintermute, CoinDesk) 5-year average correlation : ~0.54 → Confirms the recent spike is part of a longer-term uptrend that began in 2020 Year-to-date performance (Jan 1 – Nov 20, 2025) : → Nasdaq 100: +20% → Bitcoin: +3–4% → BTC has significantly underperformed tech stocks despite the tight correlation Key new phenomenon in 2025 : Strong negativ...
Read more

AI Demand Drives SSD & Memory Shortages: Prices Set to Rise for a Decade (2025)

By -
Image
Nearly every analyst firm and memory maker is now warning of looming NAND and DRAM shortages that will send SSD and memory prices skyrocketing over the coming months and years, with some even predicting a shortage that will last a decade. The shortages are becoming impossible to ignore, and warnings from the industry are growing dire, as the voracious appetite of AI data centers begins to consume the lion's share of the world's memory and flash production capacity. For the better part of two years, storage upgrades have been a rare bright spot for PC builders. SSD prices cratered to all-time lows in 2023 , with high-performance NVMe drives selling for little more than the cost of a modest mechanical hard disk. DRAM followed a similar trajectory, dropping to price points not seen in nearly a decade. In 2024, the pendulum swung firmly in the other direction, with prices for both NAND flash and DRAM starting to climb. The shift has its roots in the cyclical na...
Read more

Top Gold ETFs to Watch in Late 2025: Best Picks for Strong Returns and Low Costs

By -
Image
As of November 2025, gold prices have surged to new all-time highs, trading around $4,000 per ounce after rallying over 50% year-to-date amid persistent inflation, geopolitical tensions, and strong central bank demand. This has propelled gold ETFs to exceptional performance, with physical gold funds delivering 40-60% YTD returns and mining-focused ETFs often exceeding 100%.  Top gold ETFs span U.S., European, and Chinese markets, providing options for physical gold exposure or leveraged mining plays. This updated overview incorporates the latest performance data, trends, and forecasts as of early November 2025, highlighting shifts since mid-year. Credit: Goldprice.org U.S. Gold ETFs U.S. gold ETFs remain dominant, with physical funds like GLD and IAU offering stability, while mining ETFs like GDX provide amplified returns amid expanding miner margins. 1. SPDR Gold MiniShares Trust (GLDM) Type : ETF Sector : Physical Gold Performance : YTD ~+51% AUM : $17.3B Reason : Cost-effective ...
Read more

November 2025 XRP ETF Inflows Update: $587M Milestone and What It Means for XRP's $3 Target

By -
Image
The XRP ETF frenzy has hit fever pitch in late November 2025, with U.S. spot products shattering expectations just days after their launches. As of November 25, cumulative net inflows across the four live U.S. spot XRP ETFs have surged to $587 million—a 40% jump from the $422 million mark earlier in the week, driven by blockbuster debuts from Grayscale and Franklin Templeton. This eclipses Solana's $568 million in altcoin ETF inflows since October, positioning XRP as the undisputed leader in non-Bitcoin/ETH crypto funds amid a broader market cooldown (Bitcoin down 4% weekly, Ethereum flat). On November 24 alone—the first trading day for Grayscale's GXRP and Franklin Templeton's XRPZ—these two funds pulled in a combined $164.1 million in net inflows, outpacing daily flows for BTC (-$151M), ETH (+$97M), and SOL (+$58M) ETFs. Grayscale snagged $67.4 million, while Franklin Templeton drew $62.6 million, pushing total assets under management (AUM) to $628.6 million across issuer...
Read more

Top 10 Pharma Companies by Market Cap in 2025

By -
Image
Here are the top 10 pharmaceutical companies by market cap. The pharmaceutical industry remains robust amid evolving market dynamics, driven by innovation, strategic expansions, and shifting healthcare policies. This 2025 update integrates the first half's (H1) financial results to provide readers with a clear snapshot of leading companies’ performance and trajectory. In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Source: CompaniesMarketCap.com Lilly—boosted by sales of its diabetes and obesity drugs Moujaro and Zepbound— projects  its sales to fall between $58 billion and $61 billion. Meanwhile, Novo—which also has been powered by sales...
Read more

Tech and Innovation ETFs in 2025: Updated Top Picks, Strategies, and Risks (December 2025)

By -
Image
As 2025 draws to a close, the technology sector remains a dominant force in global markets, propelled by accelerating advancements in artificial intelligence (AI), semiconductors, robotics, and cloud computing. The S&P 500's tech weighting exceeds 34%, while the Nasdaq-100 is even more innovation-centric. Tech and innovation ETFs continue to provide efficient, diversified access to these high-growth areas, mitigating single-stock risks while capturing upside potential. This updated guide reviews the year-end market dynamics, selection criteria, refreshed top picks (with performance through early December 2025), portfolio strategies, risks, and outlooks for 2026 and beyond. This guide explores the current market landscape, key selection criteria for ETFs, top picks for 2025, portfolio-building strategies, associated risks, and forward-looking forecasts. Whether you're a beginner investor or a seasoned portfolio manager, this resource will help you navigate the evolving world...
Read more

Top 10 ETF Picks for December 2025: Best Investments for Growth Amid AI Expansion, Defense Realignment, and Fed Policy Shifts

By -
Image
Introduction As 2025 concludes, ETFs remain a cornerstone for diversified growth investing, navigating an AI-fueled rally, escalating defense needs from global realignments, and a Fed tilting toward measured easing amid persistent inflation. This updated guide refreshes November's top picks with December data, incorporating recent market surges in semiconductors and crypto, while addressing tariff escalations and volatility. Emphasis on blending high-growth themes like AI and defense with hedges like gold and Bitcoin ensures resilience. Diversification across sectors is key to capturing upside while buffering downturns. Top 10 ETFs Selections highlight YTD performance, AUM for dependability, and anticipated growth in AI, tech, healthcare, and broad markets. Data sourced from TradingView, Yahoo Finance, and recent analyses. Ranking Methodology   YTD Performance: Based on reported or estimated returns for 2025. Higher returns rank higher, with adjustments for cr...
Read more